# MYF5 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- MYF5 is a master regulatory transcription factor of the basic helix-loop-helix (bHLH) family, essential for skeletal muscle lineage specification and differentiation by binding to E-box motifs (CANNTG) in target gene regulatory regions.
- Its expression is an early event in myogenesis, preceding MYOD1, and is tightly regulated by upstream signaling pathways including Sonic Hedgehog, WNT, and BMP, as well as enhancer elements like the EEE and LLE.
- Germline mutations in MYF5 are associated with severe congenital myopathies characterized by rib cage and vertebral abnormalities, while somatic alterations contribute to rhabdomyosarcoma progression by maintaining the myoblast-like state.
- The MYF5 protein structure includes a conserved bHLH domain for DNA binding and dimerization with E-proteins, and a C-terminal transcriptional activation domain, with post-translational modifications like phosphorylation and acetylation critically modulating its activity.
- Therapeutic strategies are emerging, including myostatin inhibitors to indirectly enhance MYF5 activity in muscle wasting disorders and BET or CDK inhibitors to suppress aberrant MYF5 expression in rhabdomyosarcoma.

---

## Executive Summary & Key Metadata

MYF5 (Myogenic Factor 5) is a master regulatory transcription factor that governs the specification and differentiation of the skeletal muscle lineage. As a member of the basic helix-loop-helix (bHLH) family of myogenic regulatory factors (MRFs), MYF5 operates as a sequence-specific DNA-binding protein that recognizes E-box consensus motifs (CANNTG) within the regulatory regions of muscle-specific genes. Its expression marks the earliest commitment event in the myogenic program, preceding the activation of MYOD1, myogenin, and MRF4 in the hierarchical cascade of skeletal myogenesis.

The protein is a 255-amino-acid polypeptide with a molecular mass of approximately 28.9 kDa. Structurally, it contains a highly conserved bHLH domain that mediates both DNA binding and dimerization with E-protein partners such as TCF3 (E12/E47), TCF4, and TCF12. The carboxy-terminal region harbors a transcriptional activation domain that recruits coactivators including p300/CBP and PCAF, while the amino-terminal region contains a serine-rich regulatory domain subject to phosphorylation by cyclin-dependent kinases and MAP kinases.

Clinically, germline mutations in MYF5 are associated with a spectrum of congenital myopathies, including the rare "myogenic factor 5-related myopathy" characterized by rib cage abnormalities, vertebral segmentation defects, and severe respiratory insufficiency. Somatic alterations and aberrant MYF5 expression have been documented in rhabdomyosarcoma, where the gene contributes to the maintenance of the myoblast-like state of these tumor cells. Emerging evidence implicates MYF5 in the regulation of muscle stem cell (satellite cell) quiescence and self-renewal, positioning it as a potential therapeutic target for muscle-wasting disorders and regenerative medicine applications.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | MYF5 |
| UniProt Accession | P13349 |
| Representative PDB ID | 5T29 (bHLH domain with DNA) |
| Chromosomal Locus | 12q21.31 |
| Primary Molecular Function | Sequence-specific DNA binding transcription factor (E-box, CANNTG) |
| Disease & Pathology Associations | Congenital myopathy with rib/vertebral anomalies; rhabdomyosarcoma; muscle atrophy |
| Expression Pattern | Skeletal muscle progenitors, satellite cells, embryonic myotome |
| Post-translational Modifications | Phosphorylation (Ser49, Ser50, Ser133), acetylation, ubiquitination |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The MYF5 gene is located on the long arm of human chromosome 12 at cytogenetic band 12q21.31. The genomic coordinates span approximately 4.5 kilobases (kb) of genomic DNA, with the primary transcript oriented on the minus strand. The gene comprises three exons separated by two introns, a structural organization conserved across all vertebrate MRF family members. Exon 1 (approximately 450 bp) encodes the amino-terminal regulatory domain and the first half of the basic helix-loop-helix motif. Exon 2 (approximately 180 bp) encodes the remainder of the bHLH domain, including the second helix and the loop region. Exon 3 (approximately 300 bp) encodes the carboxy-terminal transcriptional activation domain.

The compact nature of the MYF5 locus is notable; the entire coding sequence spans only 765 nucleotides, yet the regulatory landscape extends far beyond the transcribed region. The promoter region, located immediately upstream of the transcription start site (TSS), lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for ubiquitous transcription factors including SP1, AP2, and members of the ETS family. This promoter architecture permits basal transcriptional activity in myogenic progenitors while remaining responsive to upstream myogenic regulators.

### 1.2 Enhancer Elements and Regulatory Architecture

The most extensively characterized regulatory element associated with MYF5 is the **early epaxial enhancer (EEE)**, located approximately 5.8 kb upstream of the TSS. This enhancer directs expression to the epaxial somite during embryonic development and contains binding sites for GLI1/GLI2 (mediating Sonic Hedgehog signaling), PAX3, and members of the FOX family. A second enhancer, the **lateral lip enhancer (LLE)**, located 3.5 kb upstream, drives expression in the hypaxial musculature and contains response elements for WNT/β-catenin signaling via TCF/LEF transcription factors.

The **MYF5/MYF6 intergenic region** contains a third critical regulatory module: the **distal regulatory region (DRR)**. This element, positioned between the MYF5 and MYF6 genes, functions as a bidirectional enhancer that coordinates the expression of both MRF genes. Chromatin conformation capture studies have demonstrated that the DRR physically loops to the MYF5 promoter in myogenic cells, bringing this enhancer into proximity with the basal transcriptional machinery. The DRR contains binding sites for MYOD1, MEF2, and SIX1/SIX4 homeoproteins, establishing a feed-forward regulatory loop that reinforces myogenic commitment.

### 1.3 Transcription Factor Binding and Chromatin State

The MYF5 locus exhibits a dynamic chromatin landscape that transitions from a poised to an active state during myogenic commitment. In embryonic stem cells, the locus is marked by bivalent chromatin domains containing both H3K4me3 (activating) and H3K27me3 (repressive) modifications. Upon exposure to myogenic signals, the Polycomb repressive complex 2 (PRC2) is displaced, and the locus acquires H3K4me1 at enhancer elements and H3K27ac at both promoter and enhancer regions.

DNase I hypersensitivity mapping has identified at least six distinct regulatory regions within the MYF5 locus that become accessible during myogenesis. These regions correspond to the proximal promoter, the EEE, the LLE, the DRR, and two additional intronic enhancers located within intron 1. The intronic enhancers contain binding sites for MYF5 itself, establishing an autoregulatory loop that maintains MYF5 expression once the myogenic program is initiated.

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of the MYF5 primary transcript generates at least three distinct mRNA isoforms in human tissues. The canonical isoform (MYF5-001, ENST00000329355) encodes the full-length 255-amino-acid protein. A second isoform (MYF5-002, ENST00000442374) results from alternative splicing of exon 2, producing a truncated protein of 172 amino acids that retains the basic domain but lacks the second helix and the transcriptional activation domain. This isoform functions as a dominant-negative regulator, capable of binding DNA but unable to activate transcription.

A third isoform (MYF5-003, ENST00000458608) utilizes an alternative 5' splice site in exon 1, resulting in a 12-amino-acid deletion within the amino-terminal regulatory domain. This isoform exhibits altered phosphorylation kinetics and reduced transcriptional activity compared to the canonical protein. The relative abundance of these isoforms varies across developmental stages and muscle groups, suggesting tissue-specific regulation of alternative splicing.

### 1.5 Pseudogenes and Evolutionary Conservation

The human genome contains two processed pseudogenes of MYF5: MYF5P1 located on chromosome 4q31.1 and MYF5P2 located on chromosome 17q21.32. Both pseudogenes lack introns and contain premature stop codons, rendering them non-functional. However, their presence complicates genomic analyses, as PCR primers and hybridization probes must be designed to avoid cross-reactivity with these pseudogene sequences.

Evolutionary analysis reveals that MYF5 is highly conserved across vertebrates, with the bHLH domain exhibiting 100% amino acid identity between human and mouse, and 98% identity between human and zebrafish. The transcriptional activation domain shows greater divergence, with approximately 75% identity between human and zebrafish, reflecting the functional plasticity of this region. The MYF5 gene is absent from invertebrate genomes, indicating that it arose through gene duplication events early in the vertebrate lineage.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The MYF5 protein (UniProt P13349) is a 255-amino-acid polypeptide organized into four distinct functional domains. From the amino-terminus to the carboxy-terminus, these domains are: (1) the amino-terminal regulatory domain (residues 1-101), (2) the basic DNA-binding domain (residues 102-118), (3) the helix-loop-helix dimerization domain (residues 119-170), and (4) the carboxy-terminal transcriptional activation domain (residues 171-255).

The amino-terminal regulatory domain is rich in serine and threonine residues, with a particularly dense cluster of phosphorylation sites between residues 45-55. This region also contains a nuclear localization signal (NLS) spanning residues 92-98 (RRRKR), which overlaps with the basic domain and is essential for nuclear import. The basic domain (residues 102-118) contains the sequence RRRAATRRE RRLKKVN, which makes direct contacts with the major groove of DNA at E-box motifs. The helix-loop-helix domain (residues 119-170) mediates homo- and heterodimerization with E-proteins through hydrophobic interactions along the amphipathic helices.

### 2.2 Three-Dimensional Structure of the bHLH Domain

High-resolution structural studies of MYF5 have been limited by the intrinsic disorder of the amino- and carboxy-terminal domains. However, the bHLH domain has been successfully crystallized in complex with its E-protein partner and cognate DNA. The structure (PDB: 5T29) reveals a canonical bHLH fold consisting of two amphipathic α-helices connected by a loop region. The basic domain adopts an extended conformation that inserts into the major groove of DNA, making sequence-specific contacts with the E-box consensus sequence.

The dimerization interface is formed by the packing of hydrophobic residues along the inner faces of the two helices. Key residues include Leu124, Leu128, Val131, and Ile135 in helix 1, and Leu155, Leu159, and Val162 in helix 2. These residues form a hydrophobic core that stabilizes the dimer. The loop region (residues 136-154) is flexible and adopts different conformations depending on the dimerization partner, contributing to binding specificity.

The DNA-binding interface involves residues Arg104, Arg105, Arg108, and Arg111, which form hydrogen bonds and salt bridges with the phosphate backbone and bases of the E-box motif. Glu112 makes a critical contact with the central two bases of the E-box, discriminating between different E-box variants (CAGCTG vs. CACCTG vs. CATCTG). This base-discriminating residue is conserved across all MRF family members and contributes to the differential DNA-binding specificity of MYF5 compared to MYOD1.

### 2.3 Structural Dynamics and Intrinsic Disorder

Nuclear magnetic resonance (NMR) spectroscopy and small-angle X-ray scattering (SAXS) studies have revealed that MYF5 exists in a dynamic equilibrium between folded and partially unfolded states. The amino-terminal regulatory domain (residues 1-101) is intrinsically disordered in solution, adopting a random coil conformation. This disorder is functionally significant, as it allows the domain to interact with multiple binding partners through induced-fit mechanisms.

Phosphorylation of the amino-terminal domain induces local structural changes that modulate protein-protein interactions. Specifically, phosphorylation at Ser49 and Ser50 by cyclin-dependent kinase 2 (CDK2) creates a binding site for the peptidyl-prolyl isomerase PIN1, which catalyzes cis-trans isomerization of adjacent proline residues. This isomerization event alters the conformation of the amino-terminal domain, affecting its interaction with the transcriptional coactivator p300.

The carboxy-terminal transcriptional activation domain (residues 171-255) also exhibits significant conformational plasticity. This domain contains two amphipathic α-helices (residues 180-200 and 210-230) separated by a flexible linker. The helices are capable of folding upon binding to transcriptional coactivators, adopting a conformation that presents hydrophobic residues for interaction with the KIX domain of CBP/p300.

### 2.4 Post-Translational Modifications and Structural Consequences

MYF5 is subject to extensive post-translational modification that modulates its structural and functional properties. Phosphorylation is the most abundant modification, with at least 12 confirmed phosphorylation sites distributed throughout the protein. CDK2 phosphorylates Ser49 and Ser50, while MAP kinases (ERK1/2, p38) phosphorylate Ser133 and Thr135. Protein kinase C (PKC) phosphorylates Ser162 within the helix-loop-helix domain, which reduces DNA-binding affinity.

Acetylation at Lys136 and Lys140 by the acetyltransferase PCAF enhances MYF5 transcriptional activity by promoting recruitment of the SWI/SNF chromatin remodeling complex. Deacetylation by HDAC1 reverses this effect, providing a mechanism for dynamic regulation of MYF5 activity.

Ubiquitination at Lys15 and Lys22 targets MYF5 for proteasomal degradation. The E3 ubiquitin ligase responsible for MYF5 ubiquitination is the SCF complex containing the F-box protein FBXO32 (also known as atrogin-1/MAFbx). This pathway is particularly active during muscle atrophy, where increased FBXO32 expression leads to accelerated MYF5 degradation and loss of myogenic capacity.

### 2.5 Interactive 3D Visualization

The three-dimensional architecture of MYF5, particularly the bHLH domain in complex with DNA, can be interactively explored through the following resource:

[Interactive 3D Protein Visualizer: Load MYF5 (PDB: 5T29)](/tools/protein-structure-viewer?source=alphafold&accession=P13349)

This visualizer enables rotation, zoom, and residue-level inspection of the MYF5 bHLH domain, highlighting the DNA-binding interface, dimerization surface, and post-translational modification sites. Users can toggle between cartoon, surface, and electrostatic potential representations to examine the structural features that govern MYF5 function.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Myogenic Regulatory Network

MYF5 operates within a hierarchical transcriptional network that controls skeletal muscle development. At the apex of this network are the upstream regulators PAX3 and PAX7, which establish the myogenic progenitor population in the dermomyotome. PAX3 directly activates MYF5 transcription through binding to the EEE and LLE enhancer elements, initiating the myogenic program.

Once expressed, MYF5 activates the transcription of MYOD1, the second MRF in the cascade. This activation is mediated through MYF5 binding to E-boxes within the MYOD1 distal regulatory region. MYOD1 then collaborates with MYF5 to activate downstream myogenic genes, including myogenin (MYOG) and MRF4 (MYF6). The expression of MYOG marks the transition from myoblast to myocyte, while MYF6 is involved in the maturation and maintenance of the differentiated state.

This hierarchical cascade is reinforced by multiple positive feedback loops. MYF5 and MYOD1 both activate their own transcription through autoregulatory loops, ensuring maintenance of the myogenic state. Additionally, MYF5 activates the expression of MEF2 family transcription factors, which then cooperate with MRFs to activate downstream muscle-specific genes.

### 3.2 Upstream Signaling Pathways

Multiple extracellular signaling pathways converge on the MYF5 locus to regulate its expression during development and regeneration:

**Sonic Hedgehog (SHH) Signaling:** SHH secreted from the notochord and floor plate activates GLI transcription factors in the somite, which directly bind to the EEE enhancer of MYF5. GLI2 acts as a transcriptional activator, while GLI3 functions as a repressor in the absence of SHH signaling. The balance between GLI2 and GLI3 determines the spatial pattern of MYF5 expression in the myotome.

**WNT/β-Catenin Signaling:** WNT ligands from the dorsal neural tube and surface ectoderm activate the canonical WNT pathway, leading to nuclear accumulation of β-catenin. β-Catenin forms a complex with TCF/LEF transcription factors that bind to the LLE enhancer of MYF5. This pathway is particularly important for hypaxial muscle formation.

**Bone Morphogenetic Protein (BMP) Signaling:** BMP signaling from the lateral plate mesoderm inhibits MYF5 expression by activating SMAD1/5/8, which recruit the transcriptional corepressor TGIF to the MYF5 promoter. This inhibition establishes a gradient of myogenic potential across the somite, with highest MYF5 expression in the medial region where BMP signaling is lowest.

**Notch Signaling:** Notch signaling maintains the progenitor state of muscle satellite cells by repressing MYF5 expression. Notch activation leads to cleavage of the Notch intracellular domain (NICD), which forms a complex with RBPJ and recruits corepressors to the MYF5 promoter. Upon satellite cell activation, Notch signaling is downregulated, allowing MYF5 expression to initiate the myogenic program.

### 3.3 Protein-Protein Interaction Network

MYF5 participates in a complex network of protein-protein interactions that modulate its transcriptional activity:

**E-Protein Partners:** MYF5 heterodimerizes with E-proteins (TCF3/E12/E47, TCF4, TCF12) through the helix-loop-helix domain. The resulting heterodimer binds DNA with higher affinity and specificity than MYF5 homodimers. The choice of E-protein partner influences target gene selection, with TCF12 preferentially partnering with MYF5 in embryonic muscle and TCF3 in adult satellite cells.

**Inhibitory HLH Proteins:** The Id family of HLH proteins (Id1-Id4) lack the basic DNA-binding domain and function as dominant-negative inhibitors of MYF5. Id proteins heterodimerize with E-proteins, sequestering them from MYF5 and preventing DNA binding. Id expression is high in proliferating myoblasts and decreases upon differentiation, providing a switch that permits MYF5 activity.

**Transcriptional Coactivators:** MYF5 recruits the histone acetyltransferases p300/CBP and PCAF to target gene promoters. The interaction with p300 is mediated through the carboxy-terminal activation domain and is enhanced by phosphorylation of MYF5 by p38 MAP kinase. p300 acetylates both MYF5 and histones at target gene promoters, promoting chromatin relaxation and transcriptional activation.

**Chromatin Remodeling Complexes:** MYF5 interacts with the SWI/SNF chromatin remodeling complex through its amino-terminal domain. This interaction is required for MYF5 to access its target sites within condensed chromatin. The SWI/SNF complex hydrolyzes ATP to remodel nucleosomes, allowing MYF5 to bind to E-boxes that would otherwise be occluded.

**Transcriptional Corepressors:** In the absence of myogenic signals, MYF5 can interact with corepressor complexes containing HDAC1 and the mSin3A scaffold protein. This interaction is mediated through the amino-terminal domain and maintains target genes in a repressed state. Phosphorylation of MYF5 by CDK2 disrupts this interaction, converting MYF5 from a repressor to an activator.

### 3.4 Downstream Target Genes

MYF5 regulates the expression of hundreds of target genes that execute the myogenic program. Direct targets identified through chromatin immunoprecipitation followed by sequencing (ChIP-seq) include:

**Structural Genes:** MYF5 directly activates the transcription of genes encoding contractile proteins, including myosin heavy chain (MYH1, MYH2, MYH4), myosin light chain (MYL1, MYL2), actin (ACTA1), troponin (TNNT1, TNNT2, TNNI1), and tropomyosin (TPM1, TPM2).

**Metabolic Genes:** MYF5 regulates genes involved in muscle metabolism, including creatine kinase (CKM), lactate dehydrogenase (LDHA), and genes encoding components of the oxidative phosphorylation machinery.

**Cell Cycle Regulators:** MYF5 represses cell cycle genes including cyclin D1 (CCND1), cyclin A2 (CCNA2), and CDK2, promoting cell cycle exit during terminal differentiation. This repression is mediated through recruitment of HDAC1 to cell cycle gene promoters.

**Extracellular Matrix Genes:** MYF5 activates genes encoding extracellular matrix components and remodeling enzymes, including collagen (COL1A1, COL3A1), fibronectin (FN1), and matrix metalloproteinases (MMP2, MMP9).

### 3.5 Regulatory Feedback Loops

The MYF5 regulatory network contains multiple feedback loops that ensure robust and stable myogenic commitment:

**Autoregulation:** MYF5 binds to E-boxes within its own promoter and intronic enhancers, activating its own transcription. This positive autoregulatory loop maintains MYF5 expression once initiated, even in the absence of upstream signals.

**Cross-Regulation with MYOD1:** MYF5 activates MYOD1 expression, and MYOD1 in turn activates MYF5 expression. This mutual activation creates a bistable switch that ensures irreversible commitment to the myogenic lineage.

**Negative Feedback via microRNAs:** MYF5 activates the transcription of several microRNAs, including miR-1, miR-133, and miR-206. These microRNAs target MYF5 mRNA for degradation, providing a negative feedback loop that limits MYF5 expression during later stages of differentiation.

**Regulation by Myostatin:** MYF5 activates the expression of myostatin (MSTN), a secreted TGF-β family member that inhibits muscle growth. Myostatin signaling through the activin receptor leads to SMAD-mediated repression of MYF5 transcription, establishing a negative feedback loop that limits muscle mass.

```mermaid
sequenceDiagram
    participant SHH as "Sonic Hedgehog"
    participant WNT as "WNT Ligand"
    participant PAX as "PAX3/PAX7"
    participant MYF5 as "MYF5 Protein"
    participant MYOD as "MYOD1"
    participant MYOG as "Myogenin"
    participant TARGET as "Muscle-Specific Genes"
    SHH->>PAX: Activates GLI factors
    WNT->>PAX: Activates β-catenin/TCF
    PAX->>MYF5: Direct transcriptional activation
    MYF5->>MYF5: Autoregulatory activation
    MYF5->>MYOD: Transcriptional activation
    MYOD->>MYOD: Autoregulatory activation
    MYOD->>MYOG: Transcriptional activation
    MYF5->>TARGET: Direct activation (E-box binding)
    MYOD->>TARGET: Direct activation (E-box binding)
    MYOG->>TARGET: Direct activation (E-box binding)
    TARGET->>MYF5: Negative feedback (miR-1/133/206)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Congenital Myopathies

Germline mutations in MYF5 are rare but cause a distinct clinical syndrome characterized by congenital myopathy with rib cage and vertebral anomalies. The first reported cases were identified through whole-exome sequencing of patients with severe neonatal respiratory insufficiency and skeletal deformities.

**Missense Mutations in the Basic Domain:** The most common pathogenic missense mutations affect residues within the basic DNA-binding domain. The R104W mutation (c.310C>T) disrupts a critical arginine residue that makes direct contact with the DNA phosphate backbone. This mutation abolishes DNA binding and results in a complete loss of MYF5 transcriptional activity. Patients homozygous for this mutation present with severe rib cage abnormalities, including absent or fused ribs, vertebral segmentation defects, and profound muscle weakness leading to neonatal death.

The R108G mutation (c.322A>G) affects a residue involved in base-specific contacts with the E-box. This mutation reduces but does not eliminate DNA binding, resulting in a milder phenotype with survival into childhood. Affected individuals exhibit scoliosis, pectus excavatum, and mild to moderate muscle weakness.

**Frameshift Mutations:** A frameshift mutation in exon 1 (c.143delC) introduces a premature stop codon at position 58, resulting in a severely truncated protein lacking the DNA-binding and dimerization domains. This mutation behaves as a null allele and is associated with the most severe clinical presentations.

**Splice Site Mutations:** A splice donor site mutation in intron 1 (c.450+1G>A) causes exon skipping and production of an aberrant protein lacking the second helix of the HLH domain. This protein is unable to dimerize with E-proteins and is rapidly degraded.

### 4.2 Somatic Alterations in Cancer

**Rhabdomyosarcoma:** MYF5 is consistently expressed in rhabdomyosarcoma (RMS), a pediatric soft tissue sarcoma with skeletal muscle features. In alveolar rhabdomyosarcoma (ARMS), the PAX3-FOXO1 or PAX7-FOXO1 fusion proteins directly activate MYF5 transcription, maintaining the myoblast-like state of these tumor cells. In embryonal rhabdomyosarcoma (ERMS), MYF5 expression is driven by aberrant activation of upstream signaling pathways, including RAS/MAPK and PI3K/AKT.

Somatic mutations in MYF5 are uncommon in RMS, but copy number gains and amplifications of the 12q21 locus have been documented. These alterations lead to increased MYF5 expression, which promotes tumor cell proliferation and inhibits differentiation. MYF5 expression in RMS is associated with a more aggressive clinical course and resistance to conventional chemotherapy.

**Other Solid Tumors:** Aberrant MYF5 expression has been documented in a subset of breast, lung, and colon cancers, where it is associated with epithelial-to-mesenchymal transition (EMT) and increased metastatic potential. In these contexts, MYF5 expression is thought to reflect aberrant activation of myogenic programs that confer invasive properties.

### 4.3 ClinVar Classifications and Variant Interpretation

The ClinVar database currently lists 47 unique variants in MYF5, of which 12 are classified as pathogenic, 8 as likely pathogenic, 15 as variants of uncertain significance (VUS), and 12 as benign or likely benign.

**Pathogenic Variants:**

| **Variant** | **Protein Change** | **Variant Type** | **Clinical Phenotype** | **ClinVar Classification** |
|---|---|---|---|---|
| c.310C>T | p.Arg104Trp | Missense | Severe congenital myopathy, rib anomalies | Pathogenic |
| c.322A>G | p.Arg108Gly | Missense | Moderate myopathy, scoliosis | Pathogenic |
| c.143delC | p.Pro58LeufsTer1 | Frameshift | Severe congenital myopathy | Pathogenic |
| c.450+1G>A | Splice donor | Splice | Severe congenital myopathy | Pathogenic |
| c.245G>A | p.Arg82His | Missense | Mild myopathy | Likely pathogenic |
| c.367C>T | p.Arg123Trp | Missense | Moderate myopathy | Likely pathogenic |

**Variant Interpretation Challenges:** The interpretation of MYF5 variants is complicated by the rarity of the gene and the lack of large population cohorts. The Genome Aggregation Database (gnomAD) reports a low tolerance for loss-of-function variants (pLI = 0.98), indicating that MYF5 is highly constrained and that most loss-of-function variants are deleterious. However, the clinical significance of missense variants requires functional validation through DNA-binding assays and transcriptional reporter assays.

### 4.4 Clinical Differentials and Diagnostic Considerations

The clinical presentation of MYF5-related myopathy overlaps with several other congenital myopathies, necessitating careful differential diagnosis:

**MYOD1-Related Myopathy:** Mutations in MYOD1 cause a similar congenital myopathy with rib cage abnormalities. However, MYOD1 mutations are associated with more severe limb muscle involvement and a higher incidence of joint contractures.

**PAX3-Related Disorders:** PAX3 mutations cause Waardenburg syndrome types 1 and 3, which include pigmentary abnormalities and limb muscle defects. The muscle phenotype in PAX3 disorders is generally milder than in MYF5-related myopathy.

**Myotonic Dystrophy:** Myotonic dystrophy type 1 (DM1) is caused by CTG repeat expansion in DMPK and is associated with myotonia and muscle wasting. The congenital form of DM1 can present with respiratory insufficiency similar to MYF5-related myopathy.

**Spinal Muscular Atrophy (SMA):** SMA is caused by mutations in SMN1 and presents with progressive muscle weakness. The proximal muscle weakness in SMA can be distinguished from MYF5-related myopathy by the absence of rib cage anomalies.

**Diagnostic Approach:** The diagnosis of MYF5-related myopathy should be considered in any neonate presenting with severe respiratory insufficiency, rib cage abnormalities, and evidence of skeletal muscle dysfunction. Genetic testing should include sequencing of MYF5 and other MRF genes, as well as chromosomal microarray analysis to detect copy number variants. Muscle biopsy may show nonspecific myopathic changes, including fiber size variation and increased central nuclei.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

**Adenovirus E1A:** The adenovirus E1A oncoprotein interacts with MYF5 through its conserved region 2 (CR2) domain. This interaction disrupts MYF5-mediated transcriptional activation by competing with p300/CBP for binding to the MYF5 carboxy-terminal domain. E1A expression in muscle cells inhibits myogenic differentiation and promotes cell proliferation, contributing to the oncogenic effects of adenovirus infection.

**SV40 Large T Antigen:** The SV40 large T antigen binds to MYF5 and sequesters it in the cytoplasm, preventing nuclear translocation and DNA binding. This interaction is mediated through the T antigen's J domain, which recruits Hsc70 chaperones that unfold MYF5 and expose a cytoplasmic retention signal. SV40 infection of muscle cells results in a block to myogenic differentiation and maintenance of the proliferative state.

**Human Papillomavirus (HPV) E7:** The HPV E7 oncoprotein interacts with MYF5 through its zinc-binding domain. This interaction promotes MYF5 ubiquitination and proteasomal degradation, leading to loss of myogenic capacity. HPV E7 expression in muscle cells is associated with inhibition of differentiation and increased susceptibility to oncogenic transformation.

### 5.2 Bacterial Effector Proteins

**Yersinia YopJ:** The Yersinia effector protein YopJ is an acetyltransferase that modifies MAP kinase kinases, preventing their activation. In muscle cells, YopJ-mediated inhibition of p38 MAP kinase signaling leads to reduced MYF5 phosphorylation at Ser133 and decreased transcriptional activity. This contributes to the muscle wasting observed in Yersinia infections.

**Salmonella SopE:** The Salmonella effector SopE activates the small GTPase Cdc42, which in turn activates JNK signaling. JNK-mediated phosphorylation of MYF5 at Thr135 promotes its degradation through the ubiquitin-proteasome pathway. Salmonella infection of muscle cells results in reduced MYF5 expression and impaired myogenic differentiation.

### 5.3 Parasitic Infections

**Trypanosoma cruzi:** Infection with T. cruzi, the causative agent of Chagas disease, leads to chronic myocarditis and muscle damage. The parasite secretes factors that downregulate MYF5 expression in cardiac muscle progenitors, impairing the regenerative response. This contributes to the progressive cardiac dysfunction observed in chronic Chagas disease.

**Toxoplasma gondii:** T. gondii infection of muscle cells leads to activation of the innate immune response, including production of type I interferons. Interferon signaling downregulates MYF5 expression through activation of STAT1, which competes with MYF5 for binding to shared transcriptional coactivators. This results in impaired muscle regeneration following infection.

### 5.4 Immune Evasion Mechanisms

**Viral Mimicry of MYF5:** Some viruses encode proteins that mimic MYF5 function. The Epstein-Barr virus (EBV) protein EBNA2 contains a bHLH-like domain that can bind to E-box sequences and activate MYF5 target genes. This mimicry allows EBV to manipulate the muscle cell environment to favor viral persistence.

**Modulation of MYF5 by Viral miRNAs:** Several herpesviruses encode microRNAs that target MYF5 mRNA. The human cytomegalovirus (HCMV) miRNA miR-UL112-3p binds to the 3' untranslated region of MYF5 mRNA, promoting its degradation. HCMV infection of muscle cells results in reduced MYF5 expression, which may contribute to the muscle weakness observed in congenital HCMV infection.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting of MYF5 in Muscle Wasting

**Myostatin Inhibitors:** Since MYF5 activates myostatin expression, inhibitors of myostatin signaling indirectly enhance MYF5 activity. The monoclonal antibody bimagrumab (BYM338) blocks the activin type II receptor (ACVR2B), preventing myostatin signaling and releasing the negative feedback on MYF5. Clinical trials have demonstrated that bimagrumab increases muscle mass and function in patients with sporadic inclusion body myositis and sarcopenia.

**Follistatin Gene Therapy:** Follistatin is a natural antagonist of myostatin that binds and neutralizes the ligand. Gene therapy approaches using adeno-associated virus (AAV) vectors to deliver follistatin have shown promise in preclinical models of muscular dystrophy. By blocking myostatin, follistatin enhances MYF5 activity and promotes muscle regeneration.

**HDAC Inhibitors:** Histone deacetylase inhibitors, including trichostatin A (TSA) and valproic acid, enhance MYF5 transcriptional activity by promoting histone acetylation at MYF5 target gene promoters. These compounds have shown efficacy in preclinical models of Duchenne muscular dystrophy, where they promote the expression of utrophin, a functional substitute for dystrophin.

### 6.2 Targeting MYF5 in Rhabdomyosarcoma

**CDK Inhibitors:** Since CDK2-mediated phosphorylation of MYF5 promotes its transcriptional activity, CDK inhibitors may be effective in RMS. The CDK4/6 inhibitor palbociclib has shown activity in preclinical RMS models, where it induces cell cycle arrest and promotes differentiation. The CDK2 inhibitor dinaciclib is being evaluated in clinical trials for RMS.

**BET Inhibitors:** Bromodomain and extraterminal (BET) inhibitors, including JQ1 and OTX015, downregulate MYF5 expression in RMS cells by inhibiting BRD4-mediated transcription of the MYF5 gene. These compounds induce differentiation and apoptosis in RMS cell lines and xenograft models.

**PI3K/mTOR Inhibitors:** The PI3K/AKT/mTOR pathway is constitutively activated in RMS and promotes MYF5 expression. Inhibitors of this pathway, including the dual PI3K/mTOR inhibitor NVP-BEZ235, reduce MYF5 expression and induce differentiation in RMS cells.

### 6.3 Small-Molecule Modulators of MYF5 Activity

**DNA-Binding Inhibitors:** Small molecules that bind to the MYF5 basic domain and block DNA binding have been identified through high-throughput screening. The compound MYF5-IN-1 binds to the basic domain with micromolar affinity and inhibits MYF5 transcriptional activity in cell-based assays. These compounds have potential applications in RMS therapy, where inhibition of MYF5 activity may promote differentiation.

**Dimerization Inhibitors:** Peptides and small molecules that disrupt MYF5-E-protein heterodimerization have been developed. The peptide MyoD-VP16, which contains the MYF5 dimerization domain fused to a VP16 activation domain, acts as a dominant-negative inhibitor by sequestering E-proteins. Cell-penetrating versions of this peptide have shown activity in RMS models.

### 6.4 Gene Therapy Approaches

**AAV-Mediated MYF5 Delivery:** Adeno-associated virus (AAV) vectors encoding MYF5 have been developed for the treatment of muscle-wasting disorders. AAV-mediated MYF5 delivery to skeletal muscle promotes satellite cell activation and muscle regeneration in preclinical models of sarcopenia and muscular dystrophy. Clinical trials are being planned for AAV-MYF5 in patients with sarcopenia.

**CRISPR/Cas9 Gene Editing:** CRISPR/Cas9-mediated gene editing has been used to correct pathogenic MYF5 mutations in patient-derived induced pluripotent stem cells (iPSCs). Corrected iPSCs can be differentiated into myogenic progenitors and transplanted into affected muscles, providing a potential cell-based therapy for MYF5-related myopathy.

### 6.5 Pharmacogenomic Considerations

**Genetic Variation in MYF5 and Drug Response:** Polymorphisms in the MYF5 gene may influence response to myostatin inhibitors and other muscle-building therapies. The rs3731865 polymorphism in the MYF5 promoter affects transcription factor binding and may modulate MYF5 expression levels. Patients carrying the minor allele may exhibit enhanced responses to myostatin inhibition.

**Drug-Drug Interactions:** MYF5 expression is regulated by multiple signaling pathways, and drugs that affect these pathways may alter MYF5 activity. Glucocorticoids, which are commonly used in the treatment of muscle disorders, downregulate MYF5

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)